On September 15 to 17, 2021, the 6th China Pharma IP Summit 2021 was grandly held in Shanghai. At the summit Richard Liu delivered a keynote speech and interacted with the participants, which received unanimous recognition.

The China Pharma IP Summit focused on the current hot issues and development trend of patent authorization and invalidation in the field of pharmaceutical biotechnology. It has become an international forum with considerable attention in the field of domestic pharmaceutical intellectual property rights. And the 6th summit paid more attention to controversies in the industry about the mechanism for patent linkage, patent term compensation, drug patent authorization and confirmation, the overseas drug patent protection for pharmaceutical enterprises and so on. Hundreds of people from relevant government agencies, industry associations, pharmaceutical companies, law firms, patent agencies and IP solution providers attended the Summit.

During the Summit, Richard Liu delivered keynote speech on “Issues with and trends in patent authorization, confirmation and infringement litigation regarding medicine crystalline patents”，and had a full discussion with the guests on the topic of “Examinations regarding supplementary experimental data: acceptance criteria, analysis of specific cases and trends”.

Saelink has achieved remarkable results in patent infringement litigations, patent invalidation procedure and following administrative litigations for many leading companies from different industrial fields and been highly recognized for its idea、knowledge and expertise.